Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Paediatr Perinat Epidemiol. 2015 Nov 3;30(2):190–200. doi: 10.1111/ppe.12253

Table 1.

Maternal characteristics, medication use, and immediate birth outcomes of 41,173 included pregnancies

History of triptan use No triptan history
During pregnancy N=396 Pre-pregnancy Only N=798 Migraine N=3,291 N=36,688
Age in years (Mean, SD) 30.8(4.4) 30.5(4.5) 30.3(4.5) 30.4(4.4)
BMI (kg/m2)
 <18.5 2.81 2.4 3.7 2.6
 18.5–25 59.6 59.9 61.8 66.9
 >25 37.6 37.2 34.5 30.5
Multiparous 49.2 45.9 53.5 53.4
Married or cohabitating 95.5 98.0 97.0 97.6
Mother Education
 Primary or secondary 31.1 31.8 37.0 31.0
 University or higher 68.9 68.2 63.0 69.0
Smoking during pregnancy 11.4 11.7 13.1 11.1
Alcohol during pregnancy 20.5 15.0 15.0 17.1
Folate Supplementation 60.9 62.2 57.8 59.2
Multivitamin Supplementation 37.9 43.7 38.9 37.0
Migraine Preventive Therapy 1.8 1.8 0.6 0.0
Opioids
 Pre-pregnancy 8.1 5.3 5.1 1.3
 In pregnancy 12.9 4.6 4.9 1.4
Acetaminophen
 Pre-pregnancy 46.5 47.9 44.8 25.4
 In pregnancy 76.8 70.1 63.7 42.6
NSAIDs
 Pre-pregnancy 22.0 25.9 23.3 9.9
 In pregnancy 22.5 11.2 12.6 5.9
Anti-convulsants
 Pre-pregnancy 0.5 0.5 0.2 0.1
 In pregnancy 0.3 0.3 0.3 0.2
Antidepressants
 Pre-pregnancy 5.3 4.6 3.8 2.2
 In pregnancy 2.0 1.1 1.6 0.9
Benzodiazepines
 Pre-pregnancy 1.8 1.4 0.9 0.5
 In pregnancy 1.8 0.5 0.5 0.4
Maternal depressive/anxiety symptoms1 (Mean, SD) 0.2(1.7) 0.0(1.8) 0.2(1.9) −0.2(1.6)
Pre-eclampsia 7.8 4.3 4.0 3.5
Small for Gestational Age 6.6 6.3 6.5 6.2
Apgar 5 (<7) 1.5 1.0 0.7 0.9
Preterm 4.0 4.6 4.8 4.6
Low Birth Weight 2.0 2.3 2.6 2.4
Externalizing Problems (z ≥ 1.5) 11.6 8.3 9.1 7.7
Internalizing Problems (z ≥ 1.5) 6.8 8.6 7.7 6.2
1

Figures shown are percent of column total with the exception of maternal age and depressive/anxiety symptom severity, presented as mean(standard deviation)